CGON Stock Analysis: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$52.05
-1.37 (-2.56%)
▼
5d:
-3.27%
30d:
+29.57%
90d:
+21.1%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 27, 2026
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CGON this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CGON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CGON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $52.05, which is considered fair relative to its 30-day fair value range of $42.17 to $55.51.
Technical Outlook: Technically, CGON is in a uptrend. The price is currently testing key support at $51.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $79.21 (+52.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGON is in a uptrend. The price is currently testing key support at $51.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $79.21 (+52.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$42.17 -
$55.51
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.2% below Wall St target ($79.21)
Fair Price Analysis
30-Day Fair Range
$42.17 -
$55.51
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$4.63
(8.9%)
Support & Resistance Levels
Support Level
$51.40
Resistance Level
$57.88
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-20.59
Wall Street Target
$79.21
(+52.2%)
Revenue Growth (YoY)
3774.4%
Last updated: February 01, 2026 9:17 PM ET
Data refreshes hourly during market hours. Next update: 10:17 PM
Data refreshes hourly during market hours. Next update: 10:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
5903 shares
2025-10-09
Leonard E Post
SELL
5000 shares
2025-09-30
James Mulay
SELL
12755 shares
2025-09-29
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 60 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$31 | 55 HOLD |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$75 | 51 HOLD |
